Get started
Author

Patricia Cheung

ORCID: 0009-0000-2607-1390
Observed ORCID: 0009-0000-2607-1390
OpenAlex ID: A5106622384
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
2024 · Pinkal Desai, Sagar Lonial, et al. · Clinical Cancer Research · 56
PDF
Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study
2025 · Shambavi Richard, Mahmoud Gaballa, et al. · Blood · 11
Evaluation of dual BCL-2/BCL-XL inhibition in acute myeloid leukemia preclinical models with and without prior venetoclax therapy
2026 · Reecha Shah, Nathan Kingston, et al. · Experimental Hematology · 1
Supplementary Table S1 from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
2024 · Pinkal Desai, Sagar Lonial, et al. · 1
Safety and Efficacy of AZD0120, a BCMA/CD19 Dual-Targeting CAR T-cell Therapy, in relapsed/refractory Multiple Myeloma: Preliminary Results from the DURGA-1 phase 1b/2 Study
2026 · Shambavi Richard, Mahmoud Gaballa, et al. · Transplantation and Cellular Therapy
Data from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
2024 · Pinkal Desai, Sagar Lonial, et al.
Supplementary Table S2 from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
2024 · Pinkal Desai, Sagar Lonial, et al.
Works count: 7
Citation count: 69
H-index: 2
I10-index: 2
Year
Topic
Type